Tseng Li-Lin, Huang Chun-Jen, Hsu Shu-Shong, Chen Jin-Shyr, Cheng He-Hsiung, Chang Hong-Tai, Jiann Bang-Ping, Jan Chung-Ren
Department of Dentistry, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Clin Exp Pharmacol Physiol. 2004 Oct;31(10):732-7. doi: 10.1111/j.1440-1681.2004.04087.x.
In human MG63 osteosarcoma cells, the effect of calmidazolium on Ca(2+) and proliferation was explored using fura-2 and ELISA, respectively. Calmidazolium, at concentrations greater than 0.1 micromol/L, caused a rapid increase in Ca(2+) in a concentration-dependent manner (EC(50) = 0.5 micromol/L). The calmidazolium-induced Ca(2+) increase was reduced by 66% by removal of extracellular Ca(2+). In Ca(2+)-free medium, thapsigargin, an inhibitor of the endoplasmic reticulum Ca(2+)-ATPase, caused a monophasic increase in Ca(2+), after which the effect of calmidazolium to increase Ca(2+) was completely inhibited. U73122, an inhibitor of phospholipase C (PLC), abolished histamine (but not calmidazolium)-induced increases in Ca(2+). Pretreatment with phorbol 12-myristate 13-acetate to activate protein kinase C inhibited the calmidazolium-induced increase in Ca(2+) in Ca(2+)-containing medium by 47%. Separately, it was found that overnight treatment with 2-10 micromol/L calmidazolium inhibited cell proliferation in a concentration-dependent manner. These results suggest that calmidazolium increases Ca(2+) by stimulating extracellular Ca(2+) influx and also by causing release of intracellular Ca(2+) from the endoplasmic reticulum in a PLC-independent manner. Calmidazolium may be cytotoxic to osteosarcoma cells.